Clinical Scorecard: Clinical Case Study: Metastasis to the Heart in Sarcomatoid Urothelial Carcinoma
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with sarcomatoid urothelial carcinoma, particularly those with cardiac metastasis, emphasizing the rarity and clinical implications.
Care Setting
Key Highlights
SUC accounts for fewer than 1%–2% of all urothelial malignancies, highlighting its rarity.
Cardiac metastasis from UC is exceedingly rare, with few documented cases.
This is the first documented case of isolated RV metastasis from SUC responding to anti-PD-1 therapy, underscoring its clinical significance.
Tislelizumab monotherapy resulted in significant regression of cardiac mass, indicating potential treatment pathways.
Patients intolerant to combined chemo-immunotherapy may benefit from immune checkpoint inhibitors, particularly in cases of high PD-L1 expression.
Guideline-Based Recommendations
Diagnosis
Management
Palliative robot-assisted laparoscopic nephroureterectomy for symptomatic relief, with a focus on the rationale for this approach.
First-line treatment with gemcitabine, carboplatin, and nivolumab, adjusted for renal insufficiency based on specific criteria.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Tislelizumab monotherapy was well-tolerated and effective in reducing cardiac mass, with additional context on the patient's health status and previous treatments.
Clinical Best Practices
Consider immune checkpoint inhibitors for patients with high PD-L1 expression who cannot tolerate chemotherapy, with a focus on monitoring renal function closely when selecting chemotherapy agents.
